AgeX Therapeutics Inc.
11/24/2021 | Press release | Distributed by Public on 11/24/2021 08:03
Additional Proxy Soliciting Materials (Form DEFA14A)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement |
| ☒ | Definitive Additional Materials |
| ☐ | Soliciting Material Pursuant to §240.14a-12 |
AgeX Therapeutics, Inc.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
| Payment of Filing Fee (Check the appropriate box): | |
| ☒ | No fee required. |
| ☐ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
| (1) | Title of each class of securities to which transaction applies: | |
| (2) | Aggregate number of securities to which transaction applies: | |
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined): | |
| (4) | Proposed maximum aggregate value of transaction: | |
| (5) | Total fee paid: | |
| ☐ | Fee paid previously with preliminary materials. |
| ☐ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing. |
| (1) | Amount previously paid: | |
| (2) | Form, schedule or registration statement no.: | |
| (3) | Filing party: | |
| (4) | Date filed: | |
| 1101 Marina Village Parkway, Suite 201 | |
| Alameda, CA 94501 | |
| T: 510-671-8370, F: 510-671-8619 | |
| www.agexinc.com |
Dear Fellow Shareholders,
There seems to be a coming-of-age with respect to stem cells and tissue regeneration, and we are working to capitalize on AgeX's technologies and patent estate in this field. As part of this process of optimizing opportunities for our patent estate: in 2022, we plan to seek financing for Reverse Bioengineering, Inc., our subsidiary dedicated to the advancement of our induced tissue regeneration or "iTR" technology and patents.
We are continuing our pursuit of collaborations and licensing arrangements utilizing AgeX's pluripotent stem cell lines, PureStem® progenitor cell lines, UniverCyte™ HLA-G cell transplant technology, and our cell therapy product candidates.
In the coming months, we plan to organize a new joint venture company with Prof. Leslie Thompson and other researchers at the University of California, Irvine to derive neural stem cells to treat Huntington's disease and potentially other neurological disorders. Prof. Thompson is planning to submit an IND to the United States Food and Drug Administration and a grant application for financing from the California Institute for Regenerative Medicine (CIRM) to begin a clinical study of neural stem cells in Huntington's disease next year. This new joint venture company is envisioned to be the vehicle for licensing from UC Irvine technology to derive neural stem cells if the research work we are sponsoring is successful, and to pursue clinical development and then commercialization of any approved therapeutic products that arise from Prof. Thompson's work using the licensed technology.
Under another research sponsorship, Prof. Kristin Stanford of The Ohio State University is working to generate proof-of-concept animal data for AgeX's brown adipose tissue (BAT) product candidate for diabetes and obesity, and as of now, she has performed the first transplants of our BAT cells in mice.
AgeX licensee, ImStem Biotechnology, continues to progress its mesenchymal stem cell product candidate IMS001, derived from AgeX pluripotent stem cells, for multiple sclerosis and acute respiratory distress syndrome (ARDS). Very recently, ImStem dosed the first U.S. multiple sclerosis patient with IMS001 in a clinical trial.
In addition to seeking new opportunities to work with universities and biotechnology companies to advance our platform technologies and product candidates, we will be looking for additional cellular and tissue engineering therapies to licence in or acquire to augment our pipeline in 2022. We feel there's an extraordinary opportunity for AgeX to increase its footprint in the effort to reverse the damage caused by aging.
Thank you for your patience and support as we build out our patent and technology portfolios, advance our collaboration and licensing franchise, and take advantage of opportunities to be a leader in partial reprogramming iTR technology through our subsidiary Reverse Bioengineering.
This is truly an exciting time for AgeX.
Sincerely,
| Michael D. West. Ph.D. | Gregory Bailey M.D. | ||
| President & Chief Executive Officer | Chairman of the Board |
November 24, 2021